Roche Holding Receives FDA Approval for Xolair to Reduce Allergic Reactions to Multiple Foods

By Andrea Figueras

Roche Holding announced that the U.S. Food and Drug Administration (FDA) has granted approval for Xolair, making it the first medication approved for both children and adults to decrease allergic reactions to multiple foods.

The FDA's approval is based on compelling data obtained from a study involving patients between the ages of one and 55, according to an announcement from the Swiss pharmaceutical company on Friday.

Results from the study revealed that a significantly higher percentage of food-allergy patients treated with Xolair were able to tolerate small quantities of peanuts, milk, eggs, and cashews without experiencing any allergic reactions. This is in stark contrast to individuals who were treated solely with a placebo, Roche explained.

Roche emphasizes that individuals utilizing Xolair for food allergies should continue avoiding all foods they have allergies to. While the drug is designed to alleviate allergic reactions, including anaphylaxis, which may arise from accidental exposure to these foods, it should not be utilized as emergency treatment for any allergic reactions.

Furthermore, Roche is pleased to announce that Xolair is widely accessible and can now be prescribed throughout the United States.